Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization
are main factors involved in anemia in liver disease. Lactoferrin is a first line defence
protein for protection against microbial infections and subsequent development of systemic
disease as seen with systemic inflammatory response syndrome (SIRS) and sepsis. Lactoferrin
with iron has been shown to be efficacious with anemia in chronic disease, in pregnancy and
in cancer patients with fewer side effects than oral iron alone. High exposure to iron is
associated with increased inflammation which is associated with worse cardiovascular
outcomes. Lactoferrin can help reduce the total iron dose and hepatic inflammation.
Phase:
N/A
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research